Advicenne, specializing in the development of adult and pediatric therapeutic products for the treatment of orphan renal and neurological diseases, announces that it has submitted a Marketing Authorization Application to the European Medicines Agency for its lead drug candidate, ADV7103, as a treatment for distal renal tubular acidosis.
March 12, 2019
· 5 min read